Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44354   clinical trials with a EudraCT protocol, of which   7381   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,354 result(s) found. Displaying page 2,069 of 2,218.
    «« First « Previous 2065  2066  2067  2068  2069  2070  2071  2072  2073  Next» Last»»
    EudraCT Number: 2007-000006-67 Sponsor Protocol Number: PIRRI/CT/001 Start Date*: 2007-10-29
    Sponsor Name:LALLEMAND PHARMA INTERNATIONAL
    Full Title: Sub-lingual administration of a Polyvalent Mechanical Bacterial Lysate (PMBL) in patients with Moderate or Severe and very Severe Chronic Obstructive Pulmonary Disease (COPD) according to GOLD clas...
    Medical condition: Patients with documented moderate, severe and very severe COPD.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029978 Obstructive chronic bronchitis with acute exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000302-29 Sponsor Protocol Number: AlbuCAT Start Date*: 2019-07-31
    Sponsor Name:Fundació Clinic per a la Recerca Biomèdica
    Full Title: ALBUMIN FOR MANAGEMENT OF HYPERVOLEMIC HYPONATREMIA IN PATIENTS WITH DECOMPENSATED CIRRHOSIS. A PROOF OF CONCEPT STUDY
    Medical condition: HYPERVOLEMIC HYPONATREMIA IN PATIENTS WITH DECOMPENSATED CIRRHOSIS
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10009211 Cirrhosis liver LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005178-25 Sponsor Protocol Number: 216152 Start Date*: 2022-08-22
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A Phase 1/2a, observer-blind, randomized, controlled, two-stage, multi-country study to evaluate the safety, reactogenicity, and immune response of the trivalent vaccine against invasive nontyphoid...
    Medical condition: Healthy volunteers (prevention of invasive nontyphoidal Salmonella disease and typhoid fever)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004114-17 Sponsor Protocol Number: HPV-303 Start Date*: Information not available in EudraCT
    Sponsor Name:Inovio Pharmaceuticals, Inc.
    Full Title: REVEAL 2: A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation with CELLECTRA™ 5PSP for the Treatment of HPV-1...
    Medical condition: HPV-16 and/or HPV-18 related high grade squamous intraepithelial lesion (HSIL) of the cervix
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022891 - Investigations 10064328 Human papilloma virus test positive PT
    20.0 100000004872 10066237 Cervical high grade squamous intraepithelial lesion LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) LT (Completed) EE (Completed) ES (Restarted) PL (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004695-35 Sponsor Protocol Number: CA209-8Y8 Start Date*: 2019-06-10
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined with Ipilimumab versus Nivolumab Monotherapy for Patients with Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- ...
    Medical condition: Advanced Renal Cell Carcinoma with Intermediate- or Poor-Risk Factors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) CZ (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) PT (Completed) GR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004280-32 Sponsor Protocol Number: AG10-301 Start Date*: 2019-05-10
    Sponsor Name:Eidos Therapeutics, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRIBUTE-CM Trial)
    Medical condition: Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10002020 Amyloid cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) IE (Completed) PT (Completed) ES (Ongoing) NL (Completed) BE (Completed) HU (Completed) PL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002640-23 Sponsor Protocol Number: APHP200003 Start Date*: 2020-12-14
    Sponsor Name:ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS
    Full Title: Effect of increased oxytocin doses on the mode of delivery in obese primiparous women with spontaneous labour. A double-blind, randomised, controlled trial
    Medical condition: To compare the rates of caesarean section in obese patients with spontaneous labour between two oxytocin dosage regimens
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003086-33 Sponsor Protocol Number: C0371002 Start Date*: 2020-01-28
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe he...
    Medical condition: severe to moderately severe hemophilia B <=2%
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10060614 Hemophilia B (Factor IX) LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002098-23 Sponsor Protocol Number: ALN-TTRSC02-002 Start Date*: 2019-05-09
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
    Medical condition: Hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    20.0 10010331 - Congenital, familial and genetic disorders 10019889 Hereditary neuropathic amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) BG (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) GR (Completed) NL (Trial now transitioned) CY (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002062-39 Sponsor Protocol Number: CAIN457M2302 Start Date*: 2019-01-17
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patient...
    Medical condition: hidradenitis suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) SK (Completed) CZ (Completed) BE (Completed) DK (Completed) LT (Completed) GR (Completed) NL (Completed) ES (Completed) HU (Completed) PL (Completed) BG (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002526-23 Sponsor Protocol Number: CS2514-2017-0004 Start Date*: 2019-05-07
    Sponsor Name:Entasis Therapeutics
    Full Title: A Randomized, Active-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter baumannii-calcoacetic...
    Medical condition: Infections Caused by Acinetobacter baumannii-calcoaceticus Complex
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10003999 Bacteremia LLT
    20.0 10021881 - Infections and infestations 10046577 Urinary tract infections HLT
    20.1 10021881 - Infections and infestations 10037597 Pyelonephritis acute PT
    20.0 10021881 - Infections and infestations 10076918 Hospital acquired pneumonia LLT
    20.1 10021881 - Infections and infestations 10065153 Ventilator associated pneumonia LLT
    20.0 10021881 - Infections and infestations 10078408 Surgical site infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2018-004868-57 Sponsor Protocol Number: UC-0105/1815 Start Date*: 2019-09-02
    Sponsor Name:UNICANCER
    Full Title: Phase 2, Open label Study of DS-8201a, an Anti-HER2-AntIbody Drug Conjugate (ADC) for advanced BreaSt Cancer patients, with biomarkers analysis to characterize response/resistance to therapY
    Medical condition: Adult patients with advanced breast cancer after at least a first line of chemotherapy in metastatic setting: -if HER2 IHC3+ or IHC2+/ISH+ resistant to trastuzumab and TDM-1 -if HER2 IHC0+ or IHC...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001547-32 Sponsor Protocol Number: CACZ885U2301 Start Date*: 2018-12-11
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first lin...
    Medical condition: stages AJCC v. 8 IIIB/IIIC (not eligible for definite chemoradiation therapy) or stage IV (metastatic) non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Completed) CZ (Completed) NL (Completed) GR (Completed) ES (Ongoing) IS (Completed) SK (Completed) AT (Completed) PT (Completed) DK (Completed) FI (Completed) SE (Completed) HU (Completed) IT (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000516-22 Sponsor Protocol Number: 800MS301 Start Date*: 2019-07-08
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3- Arm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 ...
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PT (Not Authorised) EE (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002611-34 Sponsor Protocol Number: 54767414MMY2036 Start Date*: 2017-10-16
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Open-label, Multicenter, Multiphase Study of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, Administered in Combination with Daratumumab, Compared with Daratumumab Alone in Subjects ...
    Medical condition: Relapsed or Refractory Multiple Myeloma (MM).
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Prematurely Ended) FR (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002110-32 Sponsor Protocol Number: 10-0065 Start Date*: 2018-06-13
    Sponsor Name:Regents of the University of Michigan
    Full Title: DMID Protocol Number: 10-0065 OVERCOME Trial: Randomized Controlled Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli
    Medical condition: Blood stream Infection (BSI) and/or pneumonia due to extensively drug-resistant Gram-negative bacilli (XDR-GNB) including XDR-AB, CRE and XDR-PA
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10004031 Bacterial infection due to other gram-negative organisms LLT
    20.1 10021881 - Infections and infestations 10035701 Pneumonia gram-negative bacterial NOS LLT
    20.1 10021881 - Infections and infestations 10064977 Acinetobacter bacteremia LLT
    20.0 10021881 - Infections and infestations 10051190 Pneumonia Pseudomonas aeruginosa LLT
    20.0 10021881 - Infections and infestations 10035679 Pneumonia due to Escherichia coli (E. Coli) LLT
    20.0 10021881 - Infections and infestations 10054280 Escherichia coli bacteraemia LLT
    20.0 10021881 - Infections and infestations 10021860 Infection Pseudomonas aeruginosa LLT
    20.1 10021881 - Infections and infestations 10023456 Klebsiella pneumonia LLT
    20.0 10021881 - Infections and infestations 10058883 Klebsiella bacteremia LLT
    20.0 10021881 - Infections and infestations 10054218 Enterobacter pneumonia PT
    20.1 10021881 - Infections and infestations 10058884 Enterobacter bacteremia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) GR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001236-19 Sponsor Protocol Number: CC-92480-MM-001 Start Date*: 2018-02-13
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 1/2 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Efficacy of CC-92480 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory ...
    Medical condition: Relapsed and refractory multiple myeloma (RRMM)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    21.1 100000004864 10067095 Multiple myeloma progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) FI (Completed) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004959-80 Sponsor Protocol Number: IIS14005 Start Date*: 2017-08-01
    Sponsor Name:Special Account For Research Funds- National and Capodistrian University of Athens
    Full Title: A randomized, pharmacodynamic comparison of ticagrelor 60mg bid vs prasugrel 5mg in patients with prior myocardial infarction
    Medical condition: In this study we aim to compare the platelet inhibition of 60mg ticagrelor bid versus 5mg prasugrel in patients with prior myocardial infarction within previous 1-3 years
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000350-19 Sponsor Protocol Number: R2810-ONC-1676 Start Date*: 2017-11-23
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: An open-label, randomized, phase 3 clinical trial of REGN2810 versus therapy of investigator's choice chemotherapy in recurrent or metastatic platinum-refractory cervical carcinoma
    Medical condition: recurrent or metastatic, platinum-refractory cervical cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) PL (Completed) GB (GB - no longer in EU/EEA) BE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003403-66 Sponsor Protocol Number: 1199.225 Start Date*: 2017-11-06
    Sponsor Name:Boehringer Ingelheim bv
    Full Title: An open-label extension trial to assess the long term safety of nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD)
    Medical condition: Systemic Sclerosis associated Interstitial Lung Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10012977 Diffuse systemic sclerosis LLT
    21.0 100000004859 10036814 Progressive systemic sclerosis LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10042954 Systemic sclerosis pulmonary PT
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10025109 Lung involvement in systemic sclerosis LLT
    21.0 100000004859 10042953 Systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) PT (Completed) GB (GB - no longer in EU/EEA) FR (Completed) DK (Completed) BE (Completed) AT (Completed) CZ (Completed) GR (Completed) SE (Completed) NO (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2065  2066  2067  2068  2069  2070  2071  2072  2073  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Aug 14 21:26:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA